Pfizer has entered into a licensing agreement with China’s 3S Bio for a cancer drug that utilizes bi-specific antibody technology, targeting PD1 and VEGF. 3S Bio is currently conducting clinical trials for this drug in China, focusing on non-small cell lung cancer, colorectal cancer, and gynecological tumors. Pfizer will pay 3S Bio $1.25 billion upfront and potentially up to $4.8 billion for the rights to develop and sell the drug outside of China. https://www.facebook.com/jeff.mah.5/videos/731145832811561/?__cft__[0]=AZUlCfwFY-atEdbJ_ODrJyPiY7An2ZxgrViHYXeCCzoRUjHIDGVE_tpTW-jbIkX4pCb9ggCnqE17eP8B7h643_ZJguYxphEAxlRqwiVUjhskLuqD88vgUylrW9oOQnd_SbXjfPlpv5pvsaJEsXuzvr69JfEQQJCI3_-U2XPlReG3NQ&__tn__=%2CO%2CP-R
